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Summary.-The present paper describes the effects of repeated administration of
rabbit anti-mouse lymphocyte serum (ALS) or normal rabbit serum (NRS) on
tumours induced in Charles-River mice by7, 12-dimethylbenz(a)anthracene (DMBA)
given at birth. ALS or NRS were given either at the time of DMBA administration
and subsequently at weekly intervals for the first 10 weeks oflife, or at daily intervals
for 7 days during the first, second, third or fourth week of life. The incidence and
histology of the tumours were studied. It was found that treatment of very young
mice with ALS greatly reduced the mean survival time of mice and significantly
increased the incidence of malignant lymphoma. The incidence of lung tumours
was found to be significantly increased in the animals injected with ALS during
the second week of life.
Treatment with ALS in the other experimental groups gave results essentially
similar to those observed in DMBA control and NRS treated mice.
ANTILYMPHOCYTE serum (ALS) and
other immunosuppressive agents have
beendescribedasfactorsenhancingtumour
incidence, this description being based on
evidence of medical therapy of human
patients as well (Allison, 1970). There
are reports of the effects of ALS on
animals treated with chemical (Fisher,
Soliman and Fisher, 1969; Balner and
Dersjant, 1969; Woods, 1969; Rabbat and
Jeejebhoy, 1970; Wagner and Haughton,
1971; Haran-Ghera and Lurie, 1971) or
viral carcinogens (Allison, Berman and
Levey, 1967; Hirsch and Murphy, 1968;
Law, Ting and Allison, 1968; Vandeputte,
1969; Burstein and Allison, 1970).
While there is evidence for an in-
creased susceptibility to the action of
oncogenic viruses following ALS treat-
ment, it was not indisputably evident that
ALS had the same enhancing effect on
chemically induced tumours. In addition,
there is relatively little in the literature on
the effects ofALS on lymphoma and other
tumours induced by 7,12-dimethylbenz-
(oc)anthracene (DMBA) given at birth in
mice. In a previous paper (Baroni et al.,
1972) we described the effects of a single
administration of ALS and normal rabbit
serum (NRS) on tumours induced by
DMBA given at birth in mice. Since both
ALS and NRS seemed equally to influence
the incidence of the tumours, we thought
it worthwhile to study the possible effects
of repeated injections of ALS and NRS
on tumours induced by DMBA given at
birth.
MATERIAL AND METHODS
Charles-River mice from the colony ofthis
Institute were used in the present experi-
ments. They are derived from a stock
obtained in 1968 and since then maintained
in our laboratory by brother x sister mating.
Newborn mice were injected subcutaneously
with 7,12-dimethylbenz(a)anthracene
(DMBA) (Eastman Organic Chemicals) ac-
cording to a procedure already described
(Rappaport and Baroni, 1962).C. D. BARONI, R. SCELSI, M. L. PERONACE AND S. UCCINI
The preparation, titration and character-
istics of ALS and NRS used in the present
studyhave beendescribedpreviously (Baroni,
Kimball andWagar, 1969; Baroni etal., 1972).
The mice were divided in 5 main groups
as follows: Group 1 treated with DMBA at
birth; Group 2 treated with DMBA at birth
and with 10 intraperitoneal injections of
0-10 ml of ALS at weekly intervals (first
injection at birth); Group 3 treated with
DMBA at birth and with 7 intraperitoneal
injections ofALS at daily intervals according
to one of the following schedules: 0 05 ml of
ALS from birth to Day 7 (Group 3A); 041 ml
of ALS from Day 8 to Day 15 (Group 3B),
0.1 ml of ALS from Day 16 to Day 21
(Group 3C), or 01 ml of ALS from Day 22
to Day 29 (Group 3D); Group 4 treated with
DMBA at birth and with NRS given as
designed for ALS in Group B to parallel
hosts; Group 5 treated with DMBA at birth
and with NRS given as designed for ALS in
Groups 3 to parallel hosts (Groups 5A, 5B,
5C, 5D).
All mice were checked weekly and ob-
served until death occurred. Few of them
were killed when moribound. The incidence
and histology of the tumours have been
determined.
After allowance for the effect ofmortality,
the chi-squared distribution on one degree of
freedom has been calculated in order to
assess the possible difference in tumour
incidence among the various experimental
groups. Since spontaneous incidence of
tumours is remarkably low in our colony of
Charles-River mice, these data are not
reported.
RESULTS
Table I shows tumour crops and sur-
vival rates. Treatment ofvery young mice
withALS (Group 3A)orchronicadministra-
tion ofthe serum for 10 weeks (Group 2)
apparentlyreducedthemeansurvivaltime.
On the other hand, administration of
ALS in the other experimental groups
had less effect on mortality. Table II pre-
sents the expected malignant lymphoma,
lungand subcutaneous tumour crops assu-
ming that DMBA, ALS and NRS treat-
ments are equally carcinogenic. In Table
III are shown the observed and expected
tumoursforallperiods consideredin Tables
I and II. In Table IV the various experi-
mental groups are compared with each
otherafterallowancefortheeffectofmorta-
lity. ItisnowclearthattreatmentwithALS
increases the number of malignant lym-
phomata only if the antiserum is adminis-
tered during the first week of life (Group
3A). In fact, the comparison of Group 1
with Group 3A and of Group 3A with
Group 5A indicates that the increased
number of malignant lymphomata ob-
served in Group 3A is statistically signifi-
cant and due to the ALS treatment.
A statistically significant increased lung
tumour count was noticed in the group
injected with ALS during the second week
of life (Group 3B).
Administration of ALS in the other
experimental groups did not influence the
incidence of tumours induced by DMBA.
DISCUSSION
We have reported in a previous paper
that a single injection of ALS was clearly
incapable either ofpreventingorincreasing
the appearance of tumours induced in
mice by DMBA given at birth (Baroni
et al., 1972). We anticipated that these
negative results could depend on timing,
dosage and number of injections of ALS.
In the present set of experiments we
observed a markedly increased number of
lymphoma bearing mice in the group
given the antiserum for the first 7 days
of life. The fact that such increase of
lymphoma induction was obtained only
in the group given ALS during the first
week of life could be explained, assuming
that malignant cellular transformation in
the lymphoid tissue starts immediately
after DMBA injection (Rappaport and
Baroni, 1962). Thus, ALS given at the
same time and shortly after DMBA
treatment (Group 3A), e.g., during thevery
initial phases of malignant transformation
(Rappaport and Baroni, 1962), could be
expected to exert rapid and long-lasting
effects on the immunocompetence of the
host, allowing unimpeded growth of
tumour cells.
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TABLE III. Observed and Expected Tumours for All Periods (From Tables I and II)
Overall observed Overall expected Ratio
Group MIL LT ST ML LT ST MIL LT ST
1 11 13 3 9.04 20-23 2-44 1-21 0(64 1-22
2 15 18 6 11-20 20-66 3-02 1-33 0-87 1-98
3A 9 8 2 2-83 9-38 1-31 3-18 0-85 1-52
3B 8 19 3 10-23 5-37 3-06 0-78 3-53 0-98
3C 7 9 2 5-61 7-82 2-20 1-24 1-15 0 90
3D 6 12) 2 9-63 11-53 2-85 0 62 1-04 0 70
4 6 10 2 7-95 13-18 2-34 0-75 0 75 0-85
5A 7 8 2 8-24 11-34 2-86 0-84 0 70 0-69
5B 9 16 2 9-29 11-90 3-12 09-96 1-34 0-63
SC 6 8 2 7-47 14-12 1-79 080 0 56 111
5D 6 13 2 8-18 8-15 2-75 0 73 1-59 0 72
AIL Malignant lymphoma.
LT Lung tumours.
ST Subcutaneous tumoturs.
TABLE IV. Influence ofALS and NRS on
Tumour Indutction
Chi-squared for
Grouips Lung Subcutaneous
compared Lymphoma tumours tumours
1 _ ] 713 2 925 3 068
1-4 09-902 3 350 0 177
2-4 1-767 1 109 2-990
1-3A 13-875 2-786 0*491
1-5A 0-610 3-566 0*386
3A-5A 13-637 1-186 0-621
1-3B (0910 37 178 0-129
1-SB 0*433 3 - 995 0 529
313-5B 0 495 36-007 0 402
1-3C 0-768 2-761 0-146
1-SC 0-713 5-235 0-152
3C-5C 0 633 2-830 0-042
1-3D 1-792 2-602 0 266
1-5D 1-004 5 469 0-332
3D-SD 1-948 2 905 0 342
1 degree of freedom: 5% = 3 841
10% = 6635
The present results h.ave also demon-
strated that treatment with ALS after
DMBA does not significantly affect lym-
phoma induction. These data suggestthat
ALS fails to exert an immunosuppressive
effect upon that part of the immune
system already committed by the newly
formed malignant lymphoma tumour
specific transplantation antigens.
A noteworthy feature was also the
increased incidence of lung tumours ob-
served in the group given ALS during the
second week of life (Group 3B). This
finding could be tentatively explained
assuming that lung cells are less sus-
ceptible to the action of DMBA than
lymphoid cells, and consequently lung
cellular malignant transformation starts
later. Ifso, the immunodepression follow-
ing treatment with ALS during the second
week oflife could account for the increased
number of lung tumours observed in this
group. This in spite of the fact that in
the lung the concentration of the carcino-
gen could be expected to be higher than
in lymphoid tissues receiving their blood
supply via the greater circulation, since
the lung is the first tissue reached by
DMBA injected subcutaneously.
In conclusion, the present results
agree with those of other investigators
(Balner and Dersjant, 1969; Rabbat and
Jeejebhoy, 1970) and indicate that, under
certain experimental conditions, treat-
ment with ALS is capable of enhancing
tumours induced by DMBA given at birtlh.
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